Drug Manufacturers - General
Compare Stocks
2 / 10Stock Comparison
SRXH vs HIMS
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Equipment & Services
SRXH vs HIMS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Drug Manufacturers - General | Medical - Equipment & Services |
| Market Cap | $1M | $6.94B |
| Revenue (TTM) | $119M | $2.35B |
| Net Income (TTM) | $-11M | $128M |
| Gross Margin | 19.9% | 69.7% |
| Operating Margin | -4.9% | 4.6% |
| Forward P/E | — | 53.9x |
| Total Debt | $39M | $1.12B |
| Cash & Equiv. | $2M | $229M |
SRXH vs HIMS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 25 | May 26 | Return |
|---|---|---|---|
| SRx Health Solution… (SRXH) | 100 | 5.8 | -94.2% |
| Hims & Hers Health,… (HIMS) | 100 | 81.2 | -18.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SRXH vs HIMS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SRXH is the clearest fit if your priority is value.
- Better valuation composite
HIMS carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 59.0%, EPS growth -3.8%, 3Y rev CAGR 64.5%
- 174.3% 10Y total return vs SRXH's -94.6%
- Lower volatility, beta 2.40, current ratio 1.90x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 59.0% revenue growth vs SRXH's 28.4% | |
| Value | Better valuation composite | |
| Quality / Margins | 5.5% margin vs SRXH's -9.4% | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | -45.7% vs SRXH's -86.7% | |
| Efficiency (ROA) | 6.0% ROA vs SRXH's -22.4%, ROIC 10.7% vs -18.1% |
SRXH vs HIMS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
HIMS leads this category, winning 4 of 4 comparable metrics.
Income & Cash Flow (Last 12 Months)
HIMS is the larger business by revenue, generating $2.3B annually — 19.7x SRXH's $119M. HIMS is the more profitable business, keeping 5.5% of every revenue dollar as net income compared to SRXH's -9.4%.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $119M | $2.3B |
| EBITDAEarnings before interest/tax | — | $164M |
| Net IncomeAfter-tax profit | — | $128M |
| Free Cash FlowCash after capex | — | $73M |
| Gross MarginGross profit ÷ Revenue | +19.9% | +69.7% |
| Operating MarginEBIT ÷ Revenue | -4.9% | +4.6% |
| Net MarginNet income ÷ Revenue | -9.4% | +5.5% |
| FCF MarginFCF ÷ Revenue | +1.3% | +3.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +28.4% |
| EPS Growth (YoY)Latest quarter vs prior year | — | -27.3% |
Valuation Metrics
SRXH leads this category, winning 3 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $1M | $6.9B |
| Enterprise ValueMkt cap + debt − cash | $29M | $7.8B |
| Trailing P/EPrice ÷ TTM EPS | -0.17x | 52.71x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 53.94x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 44.46x |
| Price / SalesMarket cap ÷ Revenue | 0.02x | 2.96x |
| Price / BookPrice ÷ Book value/share | — | 12.83x |
| Price / FCFMarket cap ÷ FCF | 1.21x | 93.85x |
Profitability & Efficiency
HIMS leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), HIMS scores 4/9 vs SRXH's 3/9, reflecting mixed financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | — | +23.7% |
| ROA (TTM)Return on assets | -22.4% | +6.0% |
| ROICReturn on invested capital | -18.1% | +10.7% |
| ROCEReturn on capital employed | -98.8% | +10.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | — | 2.07x |
| Net DebtTotal debt minus cash | $37M | $892M |
| Cash & Equiv.Liquid assets | $2M | $229M |
| Total DebtShort + long-term debt | $39M | $1.1B |
| Interest CoverageEBIT ÷ Interest expense | -2.83x | — |
Total Returns (Dividends Reinvested)
HIMS leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HIMS five years ago would be worth $25,051 today (with dividends reinvested), compared to $541 for SRXH. Over the past 12 months, HIMS leads with a -45.7% total return vs SRXH's -86.7%. The 3-year compound annual growth rate (CAGR) favors HIMS at 31.4% vs SRXH's -62.2% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -52.5% | -19.5% |
| 1-Year ReturnPast 12 months | -86.7% | -45.7% |
| 3-Year ReturnCumulative with dividends | -94.6% | +126.8% |
| 5-Year ReturnCumulative with dividends | -94.6% | +150.5% |
| 10-Year ReturnCumulative with dividends | -94.6% | +174.3% |
| CAGR (3Y)Annualised 3-year return | -62.2% | +31.4% |
Risk & Volatility
Evenly matched — SRXH and HIMS each lead in 1 of 2 comparable metrics.
Risk & Volatility
SRXH is the less volatile stock with a -0.32 beta — it tends to amplify market swings less than HIMS's 2.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HIMS currently trades 38.2% from its 52-week high vs SRXH's 9.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.32x | 2.40x |
| 52-Week HighHighest price in past year | $1.25 | $70.43 |
| 52-Week LowLowest price in past year | $0.08 | $13.74 |
| % of 52W HighCurrent price vs 52-week peak | +9.0% | +38.2% |
| RSI (14)Momentum oscillator 0–100 | 41.0 | 52.8 |
| Avg Volume (50D)Average daily shares traded | 22.0M | 35.4M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold |
| Price TargetConsensus 12-month target | — | $29.67 |
| # AnalystsCovering analysts | — | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.3% |
HIMS leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). SRXH leads in 1 (Valuation Metrics). 1 tied.
SRXH vs HIMS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SRXH or HIMS a better buy right now?
For growth investors, Hims & Hers Health, Inc.
(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus 28. 4% for SRx Health Solutions Inc. (SRXH). Hims & Hers Health, Inc. (HIMS) offers the better valuation at 52. 7x trailing P/E (53. 9x forward), making it the more compelling value choice. Analysts rate Hims & Hers Health, Inc. (HIMS) a "Hold" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SRXH or HIMS?
Over the past 5 years, Hims & Hers Health, Inc.
(HIMS) delivered a total return of +150. 5%, compared to -94. 6% for SRx Health Solutions Inc. (SRXH). Over 10 years, the gap is even starker: HIMS returned +174. 3% versus SRXH's -94. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SRXH or HIMS?
By beta (market sensitivity over 5 years), SRx Health Solutions Inc.
(SRXH) is the lower-risk stock at -0. 32β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately -844% more volatile than SRXH relative to the S&P 500.
04Which is growing faster — SRXH or HIMS?
By revenue growth (latest reported year), Hims & Hers Health, Inc.
(HIMS) is pulling ahead at 59. 0% versus 28. 4% for SRx Health Solutions Inc. (SRXH). On earnings-per-share growth, the picture is similar: SRx Health Solutions Inc. grew EPS 74. 1% year-over-year, compared to -3. 8% for Hims & Hers Health, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SRXH or HIMS?
Hims & Hers Health, Inc.
(HIMS) is the more profitable company, earning 5. 5% net margin versus -9. 4% for SRx Health Solutions Inc. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HIMS leads at 5. 2% versus -4. 9% for SRXH. At the gross margin level — before operating expenses — HIMS leads at 59. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SRXH or HIMS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SRXH or HIMS better for a retirement portfolio?
For long-horizon retirement investors, SRx Health Solutions Inc.
(SRXH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 32)). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 40 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SRXH: -94. 6%, HIMS: +174. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SRXH and HIMS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.